What is BloodFlow and how can it improve MRD assessment in MM?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, What is BloodFlow and how can it improve minimal residual disease (MRD) assessment in multiple myeloma?

Paiva opens by highlighting MRD detection continuous monitoring as an unmet need for patients with multiple myeloma. BloodFlow is then outlined as a newly developed flow cytometry method to detect MRD in blood with a greater sensitivity than next-generation flow (NGF). Paiva describes how BloodFlow works using immunomagnetic enrichment of circulating plasma cells prior to NGF, as well as the range of its sensitivity (up to 10⁻⁸). The answer is closed by looking to the future of MRD assessment, including the possibility of combining different minimally invasive techniques to improve its prognostic value.